about
Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.Etiopathogenesis of autism spectrum disorders: fitting the pieces of the puzzle together.Prevalence of Congenital Cytomegalovirus Infection Assessed Through Viral Genome Detection in Dried Blood Spots in Children with Autism Spectrum Disorders.MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection.Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus.Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus.ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection.Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection.GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection.Beclabuvir for the treatment of hepatitis C.Asunaprevir for hepatitis C: a safety evaluation.Discontinued drugs in 2012 - 2013: hepatitis C virus infection.Vitamin D deficiency is a risk factor for infections in patients affected by HCV-related liver cirrhosis.Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection.The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C.Infections worsen prognosis of patients with cirrhosis irrespective of the liver disease stage.Management of chronic viral hepatitis in the hematological patient.Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosisPrevalence of HSV1/2 Congenital Infection Assessed Through Genome Detection on Dried Blood Spot in Individuals with Autism Spectrum DisordersEfficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximabPrevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: results from a prospective studySevere Vitamin D Deficiency Increases Mortality Among Patients With Liver Cirrhosis Regardless of the Presence of HCCRisk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosisUnsolved Issues in the Treatment of Spontaneous Peritonitis in Patients with Cirrhosis: Nosocomial Versus Community-acquired Infections and the Role of FungiThe serum-ascites vitamin D gradient (SADG): A novel index in spontaneous bacterial peritonitisUse of Aspergillus fumigatus real-time PCR in bronchoalveolar lavage samples (BAL) for diagnosis of invasive aspergillosis, including azole-resistant cases, in high risk haematology patients: the need for a combined use with galactomannanReal-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus InfectionInvasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn's disease
P50
Q31051529-0D827364-7861-404D-93E7-858B7B503F52Q33355755-EA3B517C-2DDF-432E-BDFF-2538912C2713Q33770824-F7477C1A-173E-456C-9EC0-C60C60CA46F0Q34411907-002B5A91-94A5-419D-8D62-6BD2F8174D3AQ34420891-6BEA3A2A-1404-4C8A-895F-D33F54FD7EB0Q34424151-870D7B9D-86F6-49D5-9671-BC57CF892DFFQ38212793-088EF46B-B801-4038-9477-29841ED67BA9Q38227425-BF895633-A26D-4DA0-A551-3AF4EDCEE28CQ38233860-3038F4BB-B040-4D55-91F6-31B8F9F86ABCQ38237281-10EADD80-B0F9-443C-99A8-C14320F84023Q38544196-1DFAC99F-D9E5-4E2D-8DD7-3B8B450EA425Q38578458-D162BCA9-B1B0-4CBD-80CB-AF31BB09FD84Q39100351-6A0948B9-3DA0-4FBE-A515-7970BD68657BQ40095394-6691386D-835F-4A83-A231-797466899974Q40157126-9C9FE571-B05F-4222-BE6D-10557B0AFD1BQ40326326-F767D84E-B15C-46E3-8BC3-3983678F372BQ50054093-63C846A8-2B0F-4873-AEAD-91DE8F2EF2A9Q50131493-25291819-6B41-4857-A0ED-1FAFA0966B48Q57485172-B008FC94-D6BC-412C-8990-27DC4AF4F5FFQ58765939-DC96CE15-1DF5-4890-8607-5E339DE42B07Q59352318-45DE0EBD-E099-4AF1-960F-00C3CD1C7805Q59356010-2630C950-7C9E-4EEA-99C4-4AD698376AEAQ64231933-46021017-62BA-4D26-B71B-58E8BF555978Q88921728-EC00DD13-4C5D-4C2C-BFFF-0740A35E8623Q90255655-9E9E2986-FA84-482E-B028-46EEFF8F3077Q90355693-BD8CB0B2-A6D1-41A6-B8C1-A557B1C6E2DDQ91502224-07FB615E-D118-49E0-8B7F-C1027DAD5C80Q92217687-7B7CD466-4FC4-4753-8021-3B91AA33A79DQ92435884-300AD5B7-D436-4EEB-8BD2-B510056D97DC
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Emanuela Zappulo
@en
Emanuela Zappulo
@nl
type
label
Emanuela Zappulo
@en
Emanuela Zappulo
@nl
prefLabel
Emanuela Zappulo
@en
Emanuela Zappulo
@nl
P31
P496
0000-0002-7660-7939